Vanderbilt Tuberculosis Center

Results from the iAdhere trial (Study 33), conducted through the TB Trials Consortium, have been published in the Annals of Internal Medicine. This randomized trial aimed to compare treatment completion and safety of once-weekly isoniazid and rifapentine for latent TB infection by self-administration versus direct observation. The results of this study support using self-administered, once-weekly isoniazid and rifapentine to treat latent TB infection in the United States, and such treatment could be considered in similar settings when DOT is not feasible. Vanderbilt and Metro Nashville Public Health Department were participating sites in this trial.
Upcoming Events
Vanderbilt Institute for Infection, Immunology, and Inflammation (VI4) Seminar Series
Clare Smith, Ph.D.
Postdoc, Sassetti Lab at Univ of Massachussetts Medical School
"Host vs. Pathogen: Genetic Interactions Underlie Tuberculosis Susceptibility"
Tuesday, November 28, 11:00-12:00pm
512 Light Hall
Global Health Grand Rounds
“Implementation Science for TB: A Brainstorm”
Monday, December 11, 11:00-12:00pm
2525 West End Ave
8th Floor Videoconference Room
Follow us on Twitter!
Subscribe to our email list.